Vikas Pathak, MD
Pulmonary Disease · Raleigh, NCNPI 1740474121
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.1%), education and consulting fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Boehringer Ingelheim at 38.6% of the total. Reporting peaked in 2020 at $14,780 and has fallen 76.1% since, to $3,537 in 2025. Among pulmonary disease clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 127 payments — averaging $248.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$12K
- Mylan Specialty L.p.$9K
- Intuitive Surgical$7K
- Pulmonx Corporation$1K
- Olympus Corporation Of The Americas$1K
- Actelion Pharmaceuticals US, Inc.$203
- plus $2K from 26 others
What the payments were for
- Consulting fees$4,40614%
- Speaking & faculty fees$16,14251%
- Travel & lodging$2,9309%
- Food & beverage$2,5958%
- Education$5,50017%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 12 | $12,184 |
| Mylan Specialty L.p. | 11 | $8,626 |
| Intuitive Surgical | 11 | $6,583 |
| Pulmonx Corporation | 9 | $1,206 |
| Olympus Corporation Of The Americas | 10 | $1,094 |
| Actelion Pharmaceuticals US, Inc. | 8 | $203 |
| Pinnacle Biologics, Inc | 1 | $200 |
| AstraZeneca | 10 | $190 |
| GSK | 10 | $176 |
| Johnson & Johnson | 2 | $136 |
| Edwards Lifesciences | 1 | $127 |
| AbbVie(2 entities) | 4 | $93 |
| Paratek Pharmaceuticals, Inc. | 4 | $65 |
| United Therapeutics Corporation | 3 | $63 |
| Novartis | 3 | $57 |
| Electromed, Inc. | 4 | $57 |
| Insmed, Inc. | 3 | $53 |
| Jazz Pharmaceuticals Inc. | 3 | $51 |
| Grifols USA, LLC | 2 | $46 |
| Bayer | 3 | $45 |
| Abbott | 1 | $41 |
| Boston Scientific | 1 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
| Shire North American Group Inc | 2 | $32 |
| Melinta Therapeutics, LLC | 1 | $31 |
| Bard Access Systems, Inc. | 1 | $28 |
| Bard Peripheral Vascular, Inc. | 1 | $27 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Harmony Biosciences LLC | 1 | $18 |
| Pfizer | 1 | $18 |
| Merck | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,572 in reported general payments places this provider in the 90th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Raleigh
- Hiren MehtaRaleigh$76K
- William HallRaleigh$21K
- Navreet SindhwaniRaleigh$15K
- Michael PritchettPinehurst$1.3M
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- Bradley IcardPinehurst$299K
- James DonohueChapel Hill$271K
- Eric MeltzerDurham$262K
- Daniel BreaultWilmington$257K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.